Researchers performed a systematic review of available reports on the therapeutic benefit of interleukin (IL)-17/T-helper 17 (Th17) axis inhibitors in patients with generalized pustular psoriasis (GPP). Read what they discovered in this article.
In this month's Innovation article, Steve Xu, M.D., FAAD, highlights a company and innovator who are using artificial intelligence to augment physician decision-making, not replace it.
Drs. López and Kaufman discuss two new studies that examine the use of ultrasound technology as a new modality for treatment of erythematotelangiectatic and refractory rosacea.
Harold J. Brody, MD, provides his best tips and tricks for superficial and medium depth chemical peels in a presentation at the 2022 ASDS Annual Meeting.
How should dermatologists feel about direct-to-consumer online companies compounding prescription formulations? Read from three experts on the topic in this article.
How should dermatologists feel about direct-to-consumer online companies compounding prescription formulations? Read from three experts on the topic in this article.
How should dermatologists feel about direct-to-consumer online companies compounding prescription formulations? Read from three experts on the topic in this article.
Hans Hofland, Ph.D, and Dr. Steve Xu shine a spotlight on Dermira and its novel topical medicine indicated for primary axillary hyperhidrosis in patients 9 years of age and older.
Todd Petersen, CEO of VitalSkin Dermatology, discusses the last part of your transition journey – ensuring a smooth, successful transition for you, your team and your patients.
Carol Soutor, M.D., writes about efficacy and safety of mind-body therapies for the treatment of various skin conditions.
Kim, who received the Marion B. Sulzberger Award at the 2024 American Academy of Dermatology Annual Meeting, discussed itch research an implications for clinical practice.
Nuogen Pharma’s mission is to deliver the first FDA-approved anti-itch medication for chronic pruritus of unknown origin (CPUO) and other chronic itch conditions.
Read one New York physician's insights on practice survival and patient care during the pandemic.
One notable change: CVS Caremark has removed the Humira biosimilar Amjevita and now prefers Hyrimoz and an unbranded biosimilar.
Patricia Richey, MD, delves into efficacy of the 1927 and 1550 nanometer lasers to prevent skin cancers.
Take a world tour of the global game-changing advances and home-grown success strategies dermatologists in the United States and abroad are using to tackle the challenges of acne.
Rocco Serrao, MD, FAAD, addresses potential barriers to access and affordability of narrowband UVB phototherapy and topical medications for vitiligo treatment, while highlighting available resources to assist patients in overcoming these obstacles.
Patients with persistently controlled atopic dermatitis who had their doses reduced were able to maintain their low disease activity.
Shahriari highlighted advanced dermatology treatments, clinical trial inclusivity, and key care strategies for complex skin conditions at Fall Clinical 2024.
Chilukuri shared that 2 new sunscreen ingredients, physalis angulata and pycnogenol, can prevent heat-induced pigmentation, offering new options for patients.
The COVID-19 vaccine, and the speed at which it was developed, is the medical breakthrough of our lifetimes.
Brella received FDA clearance last week for improving excessive underarm sweating.
An expert in dermatology discusses the intricacies of addressing anti-aging concerns in patients with diverse skin tones, emphasizing the importance of tailoring management to meet their unique needs, understanding the underlying mechanisms of aging, and appreciating the cultural nuances within patient populations.
Explore various elements that can go into a comprehensive insurance benefits package for dermatology practice employees.
Take a look at this overview of the top 5 considerations to show how CBP/β-catenin antagonists can be utilized for skin rejuvenation and anti-aging by enhancing Wnt/p300/β-catenin transcription.
David M. Pariser, MD, FACP, FAAD, secretary and a founding board member of the International Hyperhidrosis Society, discussed the latest in hyperhidrosis research and the organization’s commitment to helping clinicians treat the condition.